TL;DR: Anne Wojcicki co-founded 23andMe in 2006, turning at-home DNA testing into a mainstream consumer product and eventually taking the company public in 2021. Despite early breakthroughs in personal genomics and a Time 100 honor, 23andMe struggled with FDA regulatory setbacks, a major 2023 data breach, and mounting financial losses that led to a 2025 bankruptcy filing. Wojcicki later stepped down as CEO and pursued a bid to reacquire the company’s assets, cementing her story as one of Silicon Valley’s most dramatic founder arcs.
Few founder stories capture the highs and lows of Silicon Valley quite like Anne Wojcicki’s. She didn’t just start a company — she tried to convince an entire generation that spitting into a tube could unlock the secrets of their DNA. For a while, it worked. 23andMe became a household name, backed by celebrity endorsements, a public listing, and a reported valuation north of $3.5 billion.
Then it unraveled. A massive data breach, regulatory clashes with the FDA, and a stock price that cratered nearly to zero turned Wojcicki’s success story into a cautionary tale about the fragility of consumer biotech businesses. Her journey offers something rare: an unfiltered look at what it actually takes to commercialize science, and what happens when the business model can’t keep up with the mission.
This article breaks down how Anne Wojcicki built 23andMe from an idea into a public company, why the business hit a wall, and what her story teaches founders navigating regulated, high-stakes industries.
Who Is Anne Wojcicki and What Does She Do?
Anne Wojcicki is an American entrepreneur best known as the co-founder and former CEO of 23andMe, the consumer genetic testing company she helped launch in 2006. Wojcicki built her career at the intersection of healthcare, technology, and consumer behavior, positioning 23andMe as a way for everyday people to access their own genetic information without going through a doctor.
She’s also the middle sister in one of tech’s most recognizable families. Her older sister, Susan Wojcicki, served as CEO of YouTube for nearly a decade before her passing in 2024 — a career you can read more about in this breakdown of Susan Wojcicki’s net worth and legacy at YouTube. Her younger sister, Janet Wojcicki, is a professor of pediatrics at the University of California, San Francisco.
Anne Wojcicki was also married to Google co-founder Sergey Brin from 2007 to 2015, a period that overlapped with 23andMe’s most formative years and, according to widespread reporting at the time, brought early investment interest from Google itself.
How Did Anne Wojcicki’s Early Life and Education Shape Her Career?
Wojcicki grew up in Palo Alto, California, in a household that prized science and academic rigor. Her father, Stanley Wojcicki, chaired Stanford University’s physics department, and both of her sisters went on to have high-profile science and health careers. That environment shaped Wojcicki’s early fascination with biology and human health.
She attended Yale University, where she earned a degree in biology. Before founding 23andMe, Wojcicki worked as a healthcare investment analyst, spending time studying biotech companies from the finance side. That vantage point gave her a front-row seat to the inefficiencies of the healthcare system — and, by her own accounts in various interviews, convinced her that patients deserved more direct access to their own health data.
That belief became the founding thesis of 23andMe.
How Did Anne Wojcicki Build 23andMe From the Ground Up?
In 2006, Wojcicki co-founded 23andMe alongside Linda Avey and Paul Cusenza. The company’s name refers to the 23 pairs of chromosomes in human DNA, and its core idea was radical for the time: let consumers order a saliva-based DNA test online, mail it in, and receive insights about their ancestry and health risks directly, without a physician as the middleman.
The company launched its first product in 2007 and quickly attracted attention from Silicon Valley’s biggest names. Early investors reportedly included Google, which had a personal connection through Wojcicki’s then-husband, Sergey Brin.
What Was Anne Wojcicki’s Vision for Personal Genomics?
Wojcicki consistently framed 23andMe’s mission as democratizing access to genetic information. Rather than genetic testing being reserved for clinical settings or rare disease diagnoses, she wanted to put that knowledge directly into consumers’ hands — letting them understand ancestry, inherited traits, and potential health risks for a fraction of the cost of traditional genetic counseling.
This consumer-first approach worked. By the mid-2010s, 23andMe had tested millions of customers and built one of the largest private genetic databases in the world. In 2015, Wojcicki was named to the Time 100 list of the world’s most influential people, recognition that reflected how far she had pushed personal genomics into the mainstream.
What Challenges Did Anne Wojcicki Face With FDA Regulation?
23andMe’s momentum hit a serious obstacle in 2013, when the U.S. Food and Drug Administration ordered the company to stop marketing its health-related genetic tests. The FDA argued that 23andMe hadn’t proven its tests were accurate enough to reliably inform consumers about serious health risks, and warned that inaccurate results could lead people to make dangerous medical decisions without a doctor’s guidance.
The setback forced Wojcicki to pull health reports from the market and rebuild the company’s regulatory strategy almost from scratch. It took years of additional data and negotiation before 23andMe regained FDA authorization for specific health reports, starting in 2015 and expanding through 2017. The episode became a defining moment in Wojcicki’s leadership — a lesson in how consumer biotech companies must balance speed and accessibility against the slower, more exacting standards of medical regulation.
How Did 23andMe Go Public and What Happened Next?
In 2021, 23andMe went public through a merger with a special purpose acquisition company (SPAC) backed by entrepreneur Richard Branson’s Virgin Group. The deal valued the company at roughly $3.5 billion and gave Wojcicki a public platform to expand beyond direct-to-consumer testing into therapeutics and drug discovery, using its genetic database as a research asset.
The public listing didn’t deliver the growth investors expected. Consumer demand for one-time DNA kits slowed once the novelty wore off, and 23andMe struggled to turn its database into a sustainable, recurring revenue business. The stock price fell sharply from its debut, wiping out most of its early public market value within a few years.
The situation worsened in October 2023, when 23andMe disclosed a data breach that exposed the personal information of millions of customers, including sensitive genetic and ancestry data. The breach damaged consumer trust in a company whose entire value proposition depended on customers feeling safe sharing their DNA.
Why Did 23andMe File for Bankruptcy in 2025?
By early 2025, 23andMe’s financial position had deteriorated to the point of crisis. Facing mounting losses, declining consumer demand, and lingering reputational damage from the data breach, the company filed for Chapter 11 bankruptcy protection in March 2025. Around the same time, Anne Wojcicki resigned as CEO, ending her nearly two-decade run leading the company she co-founded.
Rather than walking away entirely, Wojcicki pursued efforts to reacquire 23andMe’s assets through a nonprofit vehicle, arguing that the company’s genetic database and mission deserved a path forward outside the traditional public markets. Her attempt to buy back the company underscored just how personally invested she remained in 23andMe’s original mission, even after the business model that carried it public had collapsed.
What Can Entrepreneurs Learn From Anne Wojcicki’s Journey?
Wojcicki’s story is a useful case study for founders building in regulated, data-sensitive industries. A few takeaways stand out:
- Regulatory risk can outweigh product-market fit. 23andMe had strong consumer demand early on, but the FDA’s 2013 intervention proved that compliance isn’t optional in healthcare-adjacent businesses.
- Trust is the real product in data-driven companies. The 2023 breach didn’t just cost money — it undermined the core promise that made customers comfortable sharing their DNA in the first place.
- Going public doesn’t solve a weak recurring revenue model. 23andMe’s reliance on one-time test kit sales, rather than subscriptions or ongoing services, made it difficult to sustain growth after the initial market saturated.
- Founders can separate personal mission from company outcome. Wojcicki’s push to reacquire 23andMe’s assets after stepping down as CEO shows that a founder’s commitment to a mission can outlast the original corporate structure built around it.
What’s Next for Anne Wojcicki and 23andMe?
Anne Wojcicki’s story isn’t a simple rise-and-fall narrative — it’s a reminder that building a category-defining company and building a durable business are two different challenges. She succeeded remarkably at the first: 23andMe fundamentally changed how millions of people think about their own genetics. The second challenge, sustaining that success through regulation, competition, and a data breach, proved far harder.
For founders watching her journey, the lesson isn’t to avoid ambitious, mission-driven ventures. It’s to build the operational and regulatory resilience to match that ambition from day one. As Wojcicki’s next chapter with 23andMe’s assets unfolds, her story will likely keep offering lessons for anyone trying to turn scientific breakthroughs into lasting businesses.
For more deep dives into the founders shaping — and sometimes struggling within — the tech industry, explore additional profiles on FounderStories.net.
Frequently Asked Questions
What company did Anne Wojcicki found?
Anne Wojcicki co-founded 23andMe in 2006 alongside Linda Avey and Paul Cusenza. The company offers direct-to-consumer genetic testing for ancestry and health insights.
Why did the FDA intervene with 23andMe?
In 2013, the FDA ordered 23andMe to stop marketing its health-related genetic tests, citing concerns that the tests hadn’t been proven accurate enough to safely inform consumers’ medical decisions without a doctor’s oversight.
Is Anne Wojcicki still the CEO of 23andMe?
No. Anne Wojcicki resigned as CEO around the time 23andMe filed for Chapter 11 bankruptcy in March 2025. She subsequently pursued a bid to reacquire the company’s assets through a nonprofit entity.
What caused 23andMe’s financial decline?
23andMe’s decline stemmed from slowing demand for one-time DNA test kits, a costly transition attempt into therapeutics, and a major 2023 data breach that damaged consumer trust in the company’s data security.
Is Anne Wojcicki related to Susan Wojcicki?
Yes. Anne Wojcicki is the middle sister of Susan Wojcicki, the former CEO of YouTube, and Janet Wojcicki, a pediatrics professor at UCSF.
